Blueprint
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of
1934
November 30,
2016
Commission File
Number 001-14978
SMITH & NEPHEW plc
(Registrant's
name)
15 Adam Street
London,
England WC2N 6LA
(Address of
registrant's principal executive offices)
[Indicate by check
mark whether the registrant files or will file annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate by check
mark if the registrant is submitting the Form 6-K in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate by check
mark if the registrant is submitting the Form 6-K in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate by check
mark whether by furnishing the information contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission pursuant
to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant in
connection with Rule 12g3-2 (b) : 82- n/a.
Graham Baker appointed Chief Financial Officer
30 November 2016
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical
technology business, today announces the appointment of
Graham Baker
as Chief Financial
Officer. He will formally
begin the role on 1 March 2017 when he will also be appointed
to the Board as an Executive
Director.
Graham joins from Alvogen, a fast-growing generic pharmaceuticals
company, where he is Chief Financial Officer. Alvogen has 35
offices globally across US, Europe and Asia and is owned by the
founder and major private equity firms led by CVC and
Temasek.
Prior to Alvogen, Graham worked for AstraZeneca PLC for 20 years,
holding multiple senior roles including, most recently, Vice
President, Finance , International (2013-2015) with responsibility
for all emerging markets, Vice President, Global Financial Services
(2010-2013) and Vice President Finance & Chief Financial
Officer, North America (2008-10).
Graham qualified as a Chartered Accountant and Chartered Tax
Advisor with Arthur Andersen. He is a British national.
Olivier Bohuon, Chief Executive Smith & Nephew,
commented:
"Graham's blue-chip experience,
deep sector knowledge and extensive exposure to established and
emerging markets set him apart as the ideal next CFO for Smith
& Nephew. He has a strong track record of delivering
operational excellence and has relevant experience across major
finance roles and geographic markets, leading large teams
responsible for significant budgets. With his hands-on approach, I
have no doubt that he will successfully ensure effective financial
stewardship for Smith & Nephew."
Graham Baker commented:
"It took a compelling opportunity to tempt me from Alvogen, but I
could not ignore the potential of this role and the business at
Smith & Nephew. I look forward to joining the Board and
working with Olivier and his team to deliver further success in the
business, as well as ensuring that the Finance function adds ever
more value, as Smith & Nephew continues its
transformation."
No
further disclosure obligations arise under paragraphs (1) to (6) of
LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect
of this appointment.
Remuneration
Mr
Baker will be paid in accordance with the Remuneration Policy
approved by shareholders in 2014, as set out in the Annual Report
2015. He will receive a base salary of £510,000 per annum and
participate in the Annual Incentive Plan (cash and equity) and the
Performance Share Plan. He will also receive a payment in lieu of
pension and standard benefits as set out in the Annual Report. An
updated Remuneration Policy will be put to shareholders for
approval at the 2017 AGM and any future awards will be subject to
performance conditions and measures in force at the time of the
award. His notice period will be 6 months, 12 months from the
Company. No additional payment will be made on
recruitment.
Enquiries
Investors
Ingeborg
Øie
+44 (0) 20 7960 2285
Smith
& Nephew
Media
Charles
Reynolds
+44 (0) 1923 477314
Smith
& Nephew
Ben
Atwell / Matthew
Cole
+44 (0) 20 3727 1000
FTI
Consulting
About Smith & Nephew
Smith
& Nephew is a global medical technology business dedicated to
helping healthcare professionals improve people's lives. With
leadership positions in Orthopaedic
Reconstruction, Advanced Wound
Management, Sports Medicine
and Trauma
& Extremities, Smith & Nephew has around 15,000
employees and a presence in more
than 100 countries. Annual sales in 2015 were more than $4.6
billion. Smith & Nephew is a member of the FTSE100 (LSE:SN,
NYSE:SNN).
For
more information about Smith & Nephew, please visit our website
www.smith-nephew.com, follow @SmithNephewplc
on Twitter or
visit
SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered
US Patent and Trademark Office.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: November
30, 2016
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary